At the Pediatric Endocrine Society Annual Meeting, Rhythm Pharmaceuticals unveiled data from their Phase 3 pediatrics trial, demonstrating the potential of setmelanotide in treating obesity in young patients. These findings, which show a significant reduction in BMI, mark a crucial step forward in addressing the unmet medical needs of children living with obesity due to POMC/LEPR deficiency or Bardet-Biedl syndrome (BBS). Additionally, Rhythm Pharmaceuticals remains on track to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2024, aiming for a label expansion to include pediatric patients.
Furthermore, Rhythm Pharmaceuticals has previously revealed their ongoing studies on RM-718, a weekly MC4R-specific agonist, and their strategic plans for addressing hypothalamic obesity in Japan. Together, these developments showcase the company’s commitment to exploring innovative therapies to combat obesity-related disorders.
Phase 3 Pediatrics Trial Results
The oral presentation at the Pediatric Endocrine Society Annual Meeting highlighted previously disclosed data from Rhythm Pharmaceuticals’ Phase 3 pediatrics trial. The study encompassed 12 patients aged 2 to under 6 years old, all of whom were diagnosed with obesity due to POMC/LEPR deficiency or BBS. Setmelanotide administered to these patients demonstrated an impressive 3.04 mean reduction in BMI-Z score and an 18.4 percent mean reduction in BMI. These results underscore the potential of setmelanotide as a promising therapeutic option for pediatric obesity.
Rhythm Pharmaceuticals’ sNDA Plan for Pediatric Patients
Rhythm Pharmaceuticals maintains its commitment to pursuing a label expansion for pediatric patients. The company plans to submit an sNDA to the FDA in the first half of 2024. This submission will be based on the comprehensive data from their Phase 3 pediatrics trial, which indicates the safety and efficacy of setmelanotide for children with obesity due to POMC/LEPR deficiency or BBS. The potential expansion of the label will allow more young patients to benefit from this novel therapy.
RM-718: A Promising Weekly MC4R-Specific Agonist
In a separate announcement, Rhythm Pharmaceuticals revealed their ongoing Phase 1 trial evaluating RM-718, a weekly MC4R-specific agonist. This three-part study aims to assess the safety, tolerability, and pharmacokinetics of RM-718. Early preclinical studies have demonstrated its potential in reducing body weight and curbing hyperphagia, without causing hyperpigmentation. These encouraging results open up new possibilities for future therapies targeting obesity.
Addressing Hypothalamic Obesity in Japan
Recognizing the significant unmet medical need, Rhythm Pharmaceuticals announced their clinical development plan for setmelanotide in treating hypothalamic obesity in Japan. The company intends to add a supplemental cohort of 12 Japanese patients to their global Phase 3 hypothalamic obesity trial. With dosing set to commence in the third quarter of 2024, Rhythm Pharmaceuticals seeks to address the estimated 5,000 to 8,000 patients living with hypothalamic obesity in Japan.
Conclusion
Rhythm Pharmaceuticals’ recent data presentation highlighting the positive outcomes of the Phase 3 pediatrics trial underscores the potential of setmelanotide as an effective treatment for obesity in young patients. Furthermore, their ongoing studies on RM-718 and strategic plans for addressing hypothalamic obesity in Japan demonstrate their commitment to advancing innovative therapies for obesity and related disorders. As the company progresses toward a label expansion for pediatric patients, healthcare professionals, patients, and their families eagerly await further breakthroughs.
Comments